Sign in
Taking people in United StatesNo phase

Pulsed Field Ablation Versus Standard Ablation for Heart Rhythm Problems

Compares pulsed field ablation with standard ablation in adults with ventricular tachycardia.

Key facts

Who runs it
Pasquale Santangeli
Where
Cleveland, United StatesSee the site
Trial code
Registry title
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
Status
Recruiting
People taking part
40 people, planned
Started
16 Jun 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • RFA Ablation
  • PFA Ablation
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart disease after a heart attack who have repeated episodes of a dangerous fast heartbeat from the lower heart chambers (ventricular tachycardia). It compares two ways of treating the heart rhythm by catheter ablation.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Ischemic heart disease with a prior heart attack. Sustained monomorphic ventricular tachycardia: at least 2 documented episodes with an ICD, at least 1 without an ICD, or VT that keeps coming back despite heart rhythm medicines or ICD interventions. Left ventricular ejection fraction of 20% or more on an ultrasound of the heart within 90 days before enrollment.
Earlier treatment
People cannot have had a catheter or surgical ablation of VT within the past 2 months. Those who already have an ICD or take rhythm medicines may join as described above.

Main reasons for not taking part

  • Idiopathic VT or a mobile blood clot in the left ventricle
  • New York Heart Association class IV heart failure or cardiogenic shock (unless due to incessant VT)
  • Acute coronary syndrome or heart surgery within the past 2 months
  • Estimated glomerular filtration rate below 30 ml/min/1.73m2
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Age ≥18 years
  • Ischemic heart disease with prior myocardial infarction
  • Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment
  • Documented sustained monomorphic VT with any of the following characteristics:; ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD); ≥1 documented episode(s) in patients without ICD; Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Who cannot take part

  • Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment)
  • Any concomitant congenital heart disease
  • Prior catheter or surgical ablation of VT within the past 2 months
  • For individuals with no pre-existing ICD: Ineligibility for an ICD implant
  • New York Heart Association class IV heart failure
  • Cardiac surgery within the past 2 months
  • Active infection
  • Severe left heart valvular heart disease (aortic/mitral stenosis or regurgitation)
  • Present mechanical heart valve
  • Clinical, laboratory or imaging evidence of active ischemia
  • Unable to provide informed consent
  • Idiopathic VT
  • Mobile LV thrombus
  • Comorbidity likely to limit survival to <12 months
  • Estimated glomerular filtration rate <30 ml/min/1.73m2
  • Thrombocytopenia or coagulopathy
  • Contraindication to heparin
  • Pregnancy or lactation
  • Anticipated need for epicardial mapping and ablation
  • Pre-existing LVAD or other hemodynamic assist device
  • cardiogenic shock unless it is due to incessant VT

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Pasquale Santangeli, MD, PhDTaking people

About the trial

What the trial wants to find out

ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.

The 2 groups in the trial

  • RFA AblationExisting treatment, for comparison

    VT ablation with ThermoCool ST, FlexAbility SE, ThermoCool ST SF or TactiFlex SE catheters

  • PFA AblationTreatment being tested

    VT ablation with FARAPOINT catheter

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pulse Field Ablation for Post-Infarction Ventricular Tachycardia: the ASCEND Pilot Study
Plain-language title
Pulsed Field Ablation Versus Standard Ablation for Heart Rhythm ProblemsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 September 2026